

**NEW RAY MEDICINE INTERNATIONAL HOLDING LTD:
THIS SHARE PLACEMENT IS JUST THE BEGINNING
OF FURTHER FUND-RAISING ACTIVITIES**

Unashamedly, one of the latest companies to come to the Hongkong Special Administrative Region (HKSAR) of the People's Republic of China (PRC) in order to pitch an Initial Public Offering (IPO) has made it very clear that, after the IPO is successful, it fully intends to raise more money, making the best possible use of its new status as a publicly listed company.

The Company is New Ray Medicine International Holding Ltd () (Code: 8180, The Growth Enterprise Market [The GEM] of The Stock Exchange of Hongkong Ltd).

At Page 291 of the Placing Prospectus, dated October 18, 2013, it is stated:

'REASONS FOR THE PLACING AND THE USE OF PROCEEDS

'Our Directors believe that the listing of the Shares on GEM could enhance our Group's profile and the net proceeds from the Placing will strengthen our Group's financial position and enable our Group to implement our business plans set out in this section. Furthermore, a public listing status on GEM will offer our Group access to the capital market for future corporate finance exercises to assist in future business development and strengthen our competitiveness.'

At Page 12 of the Placing Prospectus, Management goes one step further in its explanation as to the principle reason for floating the Company on The GEM:

'Our Directors believe that the Listing on GEM itself will be conducive to further enhancement of our Group's profile, brand recognition and also future business development of our Group. In addition, our Directors are of the view that despite the fact that underwriting fees and estimated expenses payable by us in relation to the Listing amounted to approximately HK\$29 million (based on the Placing Price of HK\$0.25 per Placing Share), which accounted for approximately 41.4% of the gross proceeds from the Placing of approximately HK\$70 million, the Listing will (i) provide our Group additional avenues to raise capital for the future business expansion; (ii) expand and diversify the shareholders base in order to reach out the institutional funds and retail investors in Hong Kong; and (iii) strengthen our Group's financial position. Our Group financed the payment of the listing expenses through our internal financial resources and the available banking facilities of our Group.'

Ergo: Stand by for more share placements!

The Placement

Management of New Ray Medicine has Placed 280 million, one-cent Shares at 25 cents Per Share.

The Placing Price Per Share was just one penny more than the Net Tangible Asset Value Per Share which was enriched by the anticipated, net proceeds of the IPO, being \$HK54,985,000.

The money, raised ... [CLICK TO ORDER FULL ARTICLE](#)

***While TARGET makes every attempt to ensure accuracy of all data published,
TARGET cannot be held responsible for any errors and/or omissions.***

*If readers feel that they would like to voice their opinions about that which
they have read in **TARGET**, please feel free to e-mail your views to
editor@targetnewspapers.com. **TARGET** does not guarantee to publish
readers' views, but reserves the right so to do subject to the laws of libel.*